A Company-Sponsored Phase 2 Clinical Trial of TPIV 110 for HER2 breast cancer.
Phase of Trial: Phase I/II
Latest Information Update: 31 May 2017
At a glance
- Drugs TPIV 110 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors TapImmune
- 31 May 2017 According to a TapImmune media release, the company expects to submit an amended investigational new drug application (IND) by year-end 2017.
- 14 Nov 2016 New trial record
- 01 Nov 2016 According to a TapImmune media release, company plans to initiate this trial in early 2017.